What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Her primary areas of investigation include Internal medicine, Surgery, Oncology, Mesothelioma and Gastroenterology.
Her Internal medicine study is mostly concerned with Gemcitabine, Phases of clinical research, Pancreatic cancer, Bevacizumab and Cancer.
Her Phases of clinical research research integrates issues from Progressive disease, Pharmacokinetics, Pharmacology, Survival rate and Tyrosine-kinase inhibitor.
Hedy L. Kindler focuses mostly in the field of Surgery, narrowing it down to matters related to Clinical trial and, in some cases, Prospective cohort study.
Hedy L. Kindler has researched Oncology in several fields, including Stage, Colorectal cancer, Irinotecan and Adenocarcinoma.
Her Mesothelioma study incorporates themes from Immunology, Systematic review, Survival analysis and Cisplatin.
Her most cited work include:
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. (1326 citations)
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) (633 citations)
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (436 citations)
What are the main themes of her work throughout her whole career to date?
Her main research concerns Internal medicine, Oncology, Mesothelioma, Chemotherapy and Surgery.
Internal medicine is closely attributed to Gastroenterology in her study.
Her work carried out in the field of Gastroenterology brings together such families of science as Irinotecan and Neutropenia.
Her work on Pemetrexed as part of general Oncology research is often related to In patient, thus linking different fields of science.
She has included themes like Pembrolizumab, Lung cancer, Clinical trial and Radiology in her Mesothelioma study.
Hedy L. Kindler usually deals with Chemotherapy and limits it to topics linked to Toxicity and Pharmacology.
She most often published in these fields:
- Internal medicine (60.26%)
- Oncology (45.03%)
- Mesothelioma (26.93%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (60.26%)
- Oncology (45.03%)
- Germline (5.74%)
In recent papers she was focusing on the following fields of study:
Her primary scientific interests are in Internal medicine, Oncology, Germline, In patient and Olaparib.
Her studies in Internal medicine integrate themes in fields like Gastroenterology and Mesothelioma.
Her Mesothelioma research includes elements of Pembrolizumab, Clinical trial, Radiology and Response Evaluation Criteria in Solid Tumors.
Her Oncology research is multidisciplinary, incorporating perspectives in Cancer, Survival rate, Clinical endpoint, Disease and Antibody.
Her work deals with themes such as Germline mutation, Cancer research and Pancreatic cancer, which intersect with Germline.
Her biological study spans a wide range of topics, including Metastatic pancreatic cancer, BRCA mutation and Progression-free survival.
Between 2018 and 2021, her most popular works were:
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (436 citations)
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. (120 citations)
- Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) (53 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Hedy L. Kindler focuses on Internal medicine, Oncology, Mesothelioma, Cancer research and Gastroenterology.
Her Internal medicine study focuses mostly on Phases of clinical research, Gemcitabine, Pancreatic cancer, Clinical endpoint and Mesothelin.
Her study in Pancreatic cancer is interdisciplinary in nature, drawing from both Chemotherapy and Germline.
Her Oncology research incorporates elements of Cancer, Germline mutation and Cisplatin.
Her work on BAP1 as part of general Mesothelioma study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
Her Gastroenterology research is multidisciplinary, relying on both Tolerability, Irinotecan, Vomiting, Perioperative and Nausea.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
